Type of Angiotensin Receptor Blockers in relation to acute pancreatitis status. Table S1B. Duration of Angiotensin Receptor Blockers usage in relation to acute pancreatitis status. Table S1C. Estimated risk of acute pancreatitis in relation to duration of ARB. (DOCX 19 kb
FigureS2. Proportion of systemic complication with three groups according to the value of TG level i...
Table S3. Duration and amount of HBV medications and interferons in patients who received them in th...
Figure S2B. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by t...
Forest plot of angiotensin II receptor blocker inhibitors (ARBs) compared with controls on cardiovas...
BackgroundAcute pancreatitis is a potentially lethal disease, with a rising incidence in the Western...
Table S1. Patient clinical characteristics by type of immune checkpoint inhibitor therapy. Table S2....
BackgroundAcute pancreatitis is a potentially lethal disease, with a rising incidence in the Western...
Table S4. Effects of ACEI and ARB on the risk of HCC in different subgroups of HBV and HCV cohorts. ...
Figure S1. Illustrative criteria of patient inclusion in the first step. (TIFF 127 kb
Patient characteristics for the overall group with those receiving an ACE inhibitor other than ramip...
Figure S2A. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by c...
List of HBV and HCV medications, diagnostic criteria of liver cirrhosis, hyperlipidemia, and alcohol...
Fontaine classification of PAD. Table S2. Linear regression analysis for insulin in diabetic subject...
Table S1. Anatomical Therapeutic Chemical codes and generic names of the chemoprevention drugs avail...
Estimation of average treatment model for ESRD in diabetic patients. Table S2. Estimation of average...
FigureS2. Proportion of systemic complication with three groups according to the value of TG level i...
Table S3. Duration and amount of HBV medications and interferons in patients who received them in th...
Figure S2B. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by t...
Forest plot of angiotensin II receptor blocker inhibitors (ARBs) compared with controls on cardiovas...
BackgroundAcute pancreatitis is a potentially lethal disease, with a rising incidence in the Western...
Table S1. Patient clinical characteristics by type of immune checkpoint inhibitor therapy. Table S2....
BackgroundAcute pancreatitis is a potentially lethal disease, with a rising incidence in the Western...
Table S4. Effects of ACEI and ARB on the risk of HCC in different subgroups of HBV and HCV cohorts. ...
Figure S1. Illustrative criteria of patient inclusion in the first step. (TIFF 127 kb
Patient characteristics for the overall group with those receiving an ACE inhibitor other than ramip...
Figure S2A. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by c...
List of HBV and HCV medications, diagnostic criteria of liver cirrhosis, hyperlipidemia, and alcohol...
Fontaine classification of PAD. Table S2. Linear regression analysis for insulin in diabetic subject...
Table S1. Anatomical Therapeutic Chemical codes and generic names of the chemoprevention drugs avail...
Estimation of average treatment model for ESRD in diabetic patients. Table S2. Estimation of average...
FigureS2. Proportion of systemic complication with three groups according to the value of TG level i...
Table S3. Duration and amount of HBV medications and interferons in patients who received them in th...
Figure S2B. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by t...